Patents Examined by Amy E Juedes
  • Patent number: 11981746
    Abstract: Provided herein are chimeric antigen receptors (CARs) for cancer therapy, and more particularly, CARs containing a scFv from an anti-MUC16 monoclonal antibody. Provided are immune effector cells containing such CARs, and methods of treating proliferative disorders.
    Type: Grant
    Filed: February 4, 2022
    Date of Patent: May 14, 2024
    Assignee: PRECIGEN, INC.
    Inventors: Helen Sabzevari, Rutul Shah
  • Patent number: 11976134
    Abstract: Provided herein are chimeric antigen receptors (CARs) for cancer therapy, and more particularly, CARs containing a scFv from an anti-MUC16 monoclonal antibody. Provided are immune effector cells containing such CARs, and methods of treating proliferative disorders.
    Type: Grant
    Filed: February 4, 2022
    Date of Patent: May 7, 2024
    Assignee: PRECIGEN, INC.
    Inventors: Helen Sabzevari, Rutul Shah
  • Patent number: 11975029
    Abstract: Disclosed herein are compositions, methods, and kits for use in treating hematopoietic malignancies, the compositions, methods, and kits comprise a cytotoxic agent targeting cells expressing a lineage-specific cell-surface protein and a population of hematopoietic cells that express the lineage-specific cell-surface protein, the hematopoietic cells being manipulated such that they do not bind the cytotoxic agent.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: May 7, 2024
    Assignee: VOR BIOPHARMA INC.
    Inventors: Joseph Bolen, Aleksandar Filip Radovic-Moreno, John Lydeard
  • Patent number: 11970545
    Abstract: A trifunctional molecule comprising a target-specific ligand, a ligand that binds a protein associated with the TCR complex and a T cell receptor signaling domain polypeptide is provided. The ligand that binds a protein associated with a TCR complex is UCHT1 with a Y182T mutation. Engineering T cells with this novel receptor engenders antigen specific activation of numerous T cell functions, including cytokine production, degranulation and cytolysis.
    Type: Grant
    Filed: March 22, 2023
    Date of Patent: April 30, 2024
    Assignee: McMaster University
    Inventors: Christopher W. Helsen, Jonathan Bramson, Anna Dvorkin-Gheva, Galina F. Denisova, Ksenia Bezverbnaya, Kenneth Anthony Mwawasi
  • Patent number: 11965173
    Abstract: There is provided a plasmid system for transfection into a cell to create a producer cell, the system comprising: a. a helper plasmid comprising a first nucleotide sequence encoding Murine leukemia virus (MLV)-derived Gag and Pol poly-proteins; b. an envelope plasmid comprising a second nucleotide sequence encoding an Env protein; c. a genome plasmid comprising a third nucleotide sequence encoding a retroviral genome, wherein the first nucleotide sequence is codon-shuffled to remove any significant regions of homology with the third nucleotide sequence; and wherein the second nucleotide sequence is codon-optimised for expression in the producer cell.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: April 23, 2024
    Assignee: AUTOLUS LIMITED
    Inventors: Martin Pulé, Paulo Fernandes, Hanna Kymalainen, Ekaterini Kotsopoulou
  • Patent number: 11957734
    Abstract: Described herein are compositions and methods for inhibiting an inflammatory or autoimmune response and for inducing immune tolerance in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an antigen presenting cell (APC)-targeted antibody operatively linked to IL-10 or a fragment thereof. The compositions and methods described herein are useful for treating inflammatory and autoimmune disorders.
    Type: Grant
    Filed: March 25, 2021
    Date of Patent: April 16, 2024
    Assignee: Baylor Research Institute
    Inventors: SangKon Oh, Sandra Zurawski, Hyemee Joo, Gerard Zurawski
  • Patent number: 11957717
    Abstract: The present invention provides an anti-human MSLN-specific antibody and an MSLN-targeting immune effector cell. Also provided is an MSLN-targeting chimeric antigen receptor modified T-cell prepared using the antibody and a use thereof.
    Type: Grant
    Filed: April 9, 2021
    Date of Patent: April 16, 2024
    Assignee: HRAIN BIOTECHNOLOGY CO., LTD.
    Inventors: Fei Huang, Tao Peng, Xuemei Zou, Pinglei Liu, Dachun Liu, Hui Huang
  • Patent number: 11952427
    Abstract: Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40 and comprise improved heavy and light chain variable regions that impart improved yield and reduced aggregation. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.
    Type: Grant
    Filed: March 15, 2022
    Date of Patent: April 9, 2024
    Assignees: Bristol-Myers Squibb Company, CytomX Therapeutics, Inc.
    Inventors: Bryan C. Barnhart, Brigitte Devaux, Aaron P. Yamniuk, Shannon L. Okada, Brenda L. Stevens, James William West
  • Patent number: 11951130
    Abstract: The present invention relates to an antigen-binding molecule comprising a heavy chain variable region comprising a heavy-chain complementarity-determining region 1 (HCDR1) comprising an amino acid sequence represented by Sequence No. 1, an HCDR2 comprising an amino acid sequence represented by Sequence No. 2, and an HCDR3 comprising an amino acid sequence represented by Sequence No. 3; a light-chain variable region comprising a light-chain complementarity-determining region 1 (LCDR1) comprising an amino acid sequence represented by Sequence No. 4, an LCDR2 comprising an amino acid sequence represented by Sequence No. 5, and an LCDR3 comprising an amino acid sequence represented by Sequence No. 6; wherein the antigen-binding molecule is a T cell receptor (TCR); and to a cell line expressing the same.
    Type: Grant
    Filed: March 1, 2021
    Date of Patent: April 9, 2024
    Assignee: Eutilex Co., Ltd.
    Inventors: Byoung S. Kwon, Young Ho Kim, Kwang Hee Kim, Ji Won Chung, Young Gyoon Chang, Bo Rim Yi, Jung Yun Lee, Seung Hyun Lee, Sun Woo Im, Jin Kyung Choi, Hyun Tae Son, Eun Hye Yoo
  • Patent number: 11952423
    Abstract: A novel antibody that can be used as an anti-tumor agent and an anti-tumor agent that comprises, as an active ingredient, a molecule containing such an antibody.
    Type: Grant
    Filed: May 16, 2023
    Date of Patent: April 9, 2024
    Assignees: MIE UNIVERSITY, DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Hiroshi Shiku, Yasushi Akahori, Kento Tanaka, Ayaka Yatsu, Junya Ichikawa, Toshiaki Ohtsuka, Shiho Kozuma, Ryuji Hashimoto, Makiko Nakayama, Naoya Shinozaki, Kensuke Nakamura, Ichiro Watanabe, Shinji Furuzono
  • Patent number: 11945876
    Abstract: Some embodiments provided herein are chimeric costimulatory antigen receptor (CoStAR), useful in adoptive cell therapy (ACT), and cells comprising the CoStAR. In some embodiments, the CoStAR can act as a modulator of cellular activity enhancing responses to defined antigens. In some embodiments, CoStAR and/or fusion proteins, nucleic acids encoding the CoStAR and therapeutic uses thereof are also provided.
    Type: Grant
    Filed: June 15, 2022
    Date of Patent: April 2, 2024
    Assignees: Instil Bio (UK) Limited, Instil Bio, Inc.
    Inventors: John Bridgeman, Robert Hawkins, Ruben Rodriguez, Gray Kueberuwa, Milena Kalaitsidou
  • Patent number: 11944672
    Abstract: The gist of the invention consists in the therapeutic vaccine for treatment of diabetes type 1 in children, which contains Treg cells CD3(+)CD4(+)CD25(high)CD127(?). Claimed too is the cell sorter used to produce the vaccine and the method of multiplying Treg cells in vitro.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: April 2, 2024
    Assignee: Gdanski Uniwersytet Medyczny
    Inventors: Piotr Trzonkowski, Malgorzata Mysliwiec, Natalia Marek-Trzonkowska
  • Patent number: 11945869
    Abstract: Provided herein are binding polypeptides that specifically bind PD-1. More specifically, provided herein are fusion proteins, including multivalent and/or multispecific constructs and chimeric antigen receptors, that bind PD-1. Also provided are pharmaceutical compositions containing the polypeptides, nucleic acid molecules encoding the polypeptides and vectors and cells thereof, and methods of use and uses of the provided PD-1 binding polypeptides for treating diseases and conditions, such as cancer.
    Type: Grant
    Filed: November 11, 2021
    Date of Patent: April 2, 2024
    Assignee: Inhibrx, Inc.
    Inventors: Rajay A. Pandit, John C. Timmer, Angelica N. Sanabria, Florian Sulzmaier, Brendan P. Eckelman
  • Patent number: 11939388
    Abstract: Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.
    Type: Grant
    Filed: June 28, 2021
    Date of Patent: March 26, 2024
    Assignees: GENMAB A/S, BioNTech SE
    Inventors: Isil Altintas, David Satijn, Rik Rademaker, Paul Parren, Friederike Gieseke, Ugur Sahin
  • Patent number: 11932686
    Abstract: The present invention relates to a novel use of regulatory T cell-specific surface protein Lrig-1, and more specifically to an immunosuppressive agent comprising siRNA which inhibits the expression of surface protein Lrig-1. In addition, the invention relates to a method for screening an immunosuppressive agent which inhibits proteins of Lrig-1 or genes encoding the proteins. As a result, an immunosuppressive agent with low side effects and high specificity can be developed.
    Type: Grant
    Filed: July 13, 2021
    Date of Patent: March 19, 2024
    Assignee: Good T Cells, Inc.
    Inventor: Sang-kyou Lee
  • Patent number: 11932871
    Abstract: Methods of culturing T cells are provided. Accordingly there is provided a method of culturing T cells comprising culturing T cells in the presence of a T cell stimulator, an exogenous CCL21 and an exogenous ICAM1, thereby culturing the T cells. Also provided are cell cultures, isolated T cells and uses of same.
    Type: Grant
    Filed: March 2, 2018
    Date of Patent: March 19, 2024
    Assignees: YEDA RESEARCH AND DEVELOPMENT CO. LTD., THE MEDICAL RESEARCH, INFRASTRUCTURE AND HEALTH SERVICES FUND OF THE TEL AVIV MEDICAL CENTER
    Inventors: Benjamin Geiger, Nir Friedman, Shimrit Lieber, Zelig Eshhar, Tova Waks, Anat Globerson Levin
  • Patent number: 11911414
    Abstract: The present is directed to compositions comprising regulatory T cell epitopes, wherein said epitopes comprises a polypeptide comprising at least a portion of SEQ NOS: 1-124 (and/or fragments and variants thereof), and optionally 1 to 12 additional amino acids distributed in any ratio on the N-terminus and/or C-terminus of the polypeptide of SEQ ID NOS: 1-124, as well as methods of producing and using the same.
    Type: Grant
    Filed: March 26, 2021
    Date of Patent: February 27, 2024
    Assignee: EpiVax Inc.
    Inventors: Anne De Groot, William Martin
  • Patent number: 11905529
    Abstract: The present disclosure provides for methods of improving the efficacy of T cells. In an aspect, the disclosure further provides for methods of enhancing the persistence of T cells for adoptive cell transfer or therapy (ACT). Cytokine sensitivity assays (CSA) and associated methodology capable of predicting the persistence of adoptively infused T Cells are further provided for by way of the instant disclosure. The disclosure also provides for methods of treating cancer in a subject in need thereof as well as T cells populations produced by methods described herein.
    Type: Grant
    Filed: October 2, 2020
    Date of Patent: February 20, 2024
    Assignee: Immatics US INC.
    Inventor: Amir Alpert
  • Patent number: 11897932
    Abstract: The present disclosure generally relates to, among other things, a new class of receptors engineered to modulate transcriptional regulation in a ligand-dependent manner. Particularly, the new receptors, even though derived from Notch, do not require the Notch negative regulatory regions previously believed to be essential for the functioning of the receptors. The disclosure also provides compositions and methods useful for producing such receptors, nucleic acids encoding same, host cells genetically modified with the nucleic acids, as well as methods for modulating an activity of a cell and/or for the treatment of various health conditions or diseases, such as cancers.
    Type: Grant
    Filed: March 30, 2021
    Date of Patent: February 13, 2024
    Assignee: The Regents of the University of California
    Inventors: Kole T. Roybal, Raymond Liu, Iowis Zhu
  • Patent number: 11897958
    Abstract: Described herein are monoclonal antibodies that bind to VSIG-4 including antibodies that block the binding of VSIG-4 to SIGLEC-7, compositions including the monoclonal antibodies, and methods of making and using those antibodies and compositions.
    Type: Grant
    Filed: August 19, 2020
    Date of Patent: February 13, 2024
    Assignee: BIO-TECHNE CORPORATION
    Inventors: Birte Aggeler, Christine Goetz, Jody Bonnevier, Christopher Carlin Valley, Christopher Hammerbeck, Ernesto Ruben Resnik